Performance Enhancing Drugs Market Overview
Performance Enhancing Drugs Market Size was valued at USD 0.38 Billion in 2023. The Global Performance Enhancing Drugs industry is projected to grow from USD 0.40 Billion in 2024 to USD 0.69 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.29% during the forecast period (2024 - 2032). As the name suggests, performance-enhancing drugs refer to those chemical agents that provide an advantage to the athlete and helps in boosting athletic performance. Enlargement of muscles, and increasing the carrying capacity of blood’s oxygen are some of the effects that are a result of consuming the performance-enhancing drugs before competition for the athletes.
As per the Health Research Funding and their conducted research in 2015, as many as, 1,084,000 Americans were known to consume the anabolic performance-enhancing drugs. Also, the other stats include the willingness of people to consume these drugs even after learning the fact that these might shorten their life span. The quantum of these stats stands at 57%. These drugs can be categorized as aids and steroids which help the athletes enjoy the physical edge during the competition. Also, the athlete is likely to have a mental state to give their best post the drug use, as well. The steroids which the athletes use is a modified testosterone version. These have medical uses but cannot be categorized as performance enhancers.
COVID 19 Analysis of Performance Enhancing Drugs Market
Since the arrival of the pandemic, the demand for performance-enhancing drugs is constant but is not experiencing any growth. The pandemic has accelerated new trends and techniques and people are questioning the quality of their life and their lifestyle. To have a better and qualitative life, people are shifting to healthier alternates and shifting to better eating habits including health supplements. Also, during the pandemic, the lockdown, social distancing, and event cancellations are reducing competition. Hence, the demand for performance-enhancing drugs is stagnant. Also, the associated health risks with the same are pushing people to opt for alternate and healthier means. While others are eliminating the use and go natural.
The key market players that are functional in major regions of the world and hence, are opting for key strategies opportunities that will help them grow by the end of the forecast period in 2024. The players are opting for product developments and enhancements through mergers and acquisitions. This has a major role to play in increasing the will for people to use these drugs and the widescale awareness, reliable information, and demand related to the same.
Performance Enhancing Drugs Market Trends
Drivers
There is an increase in the use of anabolic steroids amongst the target audience and patients having medical histories related to different kinds of diseases. Also, these drugs are presenting a reliable use for the treatment of health issues like anemia, and certain types of breast cancer alongside the others that prevail amongst the patients. These factors are playing a major role and acting as drivers to fuel the growth for the performance enhancing drugs market on a global level for the forecast period ending in 2023.
Restraints
Even though there are varied uses of such drugs, the performance enhancing drugs market is exposed to certain restraints on its way of global growth as per the prediction. The side effects due to the use of these drugs real and a matter of concern. In males, acne breakout is a common risk and there are other health issues like reduced sperm production. Females witness issues like masculinization, a higher risk of a heart attack, and others. Also, the government is proposing stricter guidelines that are restricting the performance enhancing drugs market growth during the forecast period that ends in 2023.
is exposed to certain restraints on its way of global growth as per the prediction. The side effects due to the use of these drugs real and a matter of concern. In males, acne breakout is a common risk and there are other health issues like reduced sperm production. Females witness issues like masculinization, a higher risk of a heart attack, and others. Also, the government is proposing stricter guidelines that are restricting the performance enhancing drugs market growth during the forecast period that ends in 2023.
Technology Analysis
Most of the athletes that belong to the developed and developing nations are demanding the use of performance-enhancing drugs on a large scale. There is a rise in the positive tests for anabolic drugs across the world and the figure has touched 50.6% as reported by the Health Research funding. This shows that there is a growth in the acceptance of these drugs and there is a growth in the utilization of the same for performance. The potential audience is witnessing an increase in the per capita income for people which is further pushing them to invest in the consumption of these drugs.
Study Objectives
- To understand the futuristic scope of the performance enhancing drugs market as per the market dynamics like drivers, opportunities, risks, and restraints and further predict the expected CAGR rate of growth and market evaluation
- To analyze the scope of the market by surveying the performance enhancing drugs market segments functioning across regions worldwide and also understanding their scope during the forecast period ending in 2023
- To review the market scale of operations by having an idea about the prominent companies and other key players in the mushrooming regions and also learning about the competitive degree in the performance enhancing drugs market owing to the recent developments undertaken by the companies
Performance Enhancing Drugs Market Segment
The global performance enhancing drugs market is largely dependent on the functioning of the various market segments that are available across various regions in the globe. The segments prove an understanding of the revenue cycle which further helps in predicting the market valuation. The market has been segmented based on the following:
Type
The type segment of the global performance enhancing drugs market includes ergogenic acids and nootropics amongst others. Further, the ergogenic acids have sub-segments like human growth syndrome, DHEA, anabolic steroids, and others. The nootropic segment includes racetams, acetylcholine intermediates, and ampakines, amongst others.
Product
The product segment of the global performance enhancing drugs market includes pills and patches, alongside injections on the requirement.
End-users
The market end-users are athletes and bodybuilders, militaries, and students.
Performance Enhancing Drugs Market Regional Analysis
Owing to the historic trends and efforts of the performance enhancing drugs market players present, the North American region is likely to have a dominant hand over the global market operations. The companies help in generating a high per capita income for the population in regions like Canada and the USA. this is increasing the purchasing power of the people. Also, in the historic year of 2017, the American Cancer Society functioning in the USA, reported a huge rise in the cases of women suffering from breast cancer. The number reached 252,710 and the death toll because of the same reached 40, 610. Hence, to cure such diseases and put the patients in a better position, the demand for anabolic steroids is enhancing and this will boost the global performance enhancing drugs market growth during the ongoing forecast period that ends in 2023.
Performance Enhancing Drugs Market Competitive Landscape
The report helps to analyze the competitive degree that prevails in the performance enhancing drugs market and for the same, it is mandatory to understand the prominent players that are putting efforts in these regions. The players are as follows:
- Taj Pharmaceuticals Limited. (India)
- Eli Lilly and Company. (the U.S.)
- Balkan Pharmaceuticals. (Europe)
- Onnit Labs, LLC. (the U.S.)
- Douglas Laboratories. (the U.S.)
- Bayer AG (Europe)
- BrainAlert, LLC (U.S.)
- AstraZeneca (Europe)
- Novo Nordisk A/S (Europe)
Recent Developments
- The European performance enhancing drugs market players are ensuring a constant and reliable place for the availability of funds for innovation and research. Also, the results of such drugs are promising as the people are accepting and demanding them on a large basis. This will help the market with the much-needed boost.
- The APAC companies are targeting performance enhancing drugs market growth through investing in creating awareness related to the drugs in the mushrooming economies. The market has a lot of scope and desirable opportunities that are the main target for these companies by the end of the forecast period in 2023.
- The African healthcare service providers and startups are open for mergers and acquisitions that will help the market grow and provide the target audience with these drugs. The players are largely interested in developing the healthcare sector by expanding the development expenditure.
- The US and Canadian companies are on the way to develop a treatment for issues related to the side effects and health concerns raised by the performance-enhancing drugs. This step has been taken to cater to the huge demand for the performance enhancing drugs market .
Intended Audience
- Athletes
- Persons engaged in body-building and competitions
- Students
- Wrestlers
Report Overview
The curated report is a step to understand the performance enhancing drugs market dynamics and further conduct the performance-enhancing drugs market analysis to predict the CAGR rate and market valuation by the end of the forecast period in 2023. The report discusses the impact of the pandemic on the market operations and the steps taken by the government and key market players to bounce back. The report also discusses the market segmentation that has the potential to bring a change in the final market valuation by their functioning in various regions across the globe. Also, to judge the competitive degree, the market report mentions the recent developments undertaken by the performance enhancing drugs market players for final evaluation.
Report Attribute/Metric
|
Details
|
ย ย Market Size
|
ย ย USD 0.69 Billion
|
ย ย CAGR
|
ย 7.29%
|
ย ย Base Year
|
ย ย 2021
|
ย ย Forecast Period
|
ย ย 2024-2032
|
ย ย Historical Data
|
ย ย 2020
|
ย ย Forecast Units
|
ย ย Value (USD Million)
|
ย ย Report Coverage
|
ย ย Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
ย ย Segments Covered
|
ย ย Types, Products, and End-Users
|
ย ย Geographies Covered
|
ย ย North America, Europe, Asia-Pacific, and Rest of the World (RoW)
|
ย ย Key Vendors
|
ย ย Taj Pharmaceuticals Limited. (India), Balkan Pharmaceuticals. (Europe), Bayer AG (Europe), AstraZeneca (Europe), Novo Nordisk A/S (Europe), BrainAlert, LLC (U.S.), Douglas Laboratories. (U.S.), Onnit Labs, LLC. (U.S.), Eli Lilly and Company. (U.S.)
|
ย ย Key Market Opportunities
|
ย ย Continuously Developing Economies
|
ย ย Key Market Drivers
|
ย ย Growing acceptance of performance enhancing drugs among amateur bodybuilders and fitness enthusiasts
|
ย
Performance Enhancing Drugs Market Highlights:
Frequently Asked Questions (FAQ) :
Performance enhancing drugs are drugs that elevate the consumer’s athletic performance by providing benefits such as muscle enlargement and increased oxygen carrying capacity.
The Performance Enhancing Drugs Market is expected to exhibit a strong 7.29% CAGR over the forecast period from 2024-2032.
Growing acceptance of performance enhancing drugs among amateur bodybuilders and fitness enthusiasts is the major driver for the market.
The Americas dominate the Global Performance Enhancing Drugs Market.
Leading players in the Performance Enhancing Drugs Market include Novo Nordisk, Taj Pharmaceuticals, and Bayer AG, among others.